CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosisFelix Fischbach, Nicolaus Kröger, Francis Ayuk et al.|Med|2024Cited by 161
CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple SclerosisJohanna Richter, Nicolaus Kroeger, Felix Fischbach et al.|Blood|2024Cited by 9
Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis—a systematic reviewBente Braun, Vivien Häußler, Felix Fischbach et al.|European Journal of Neurology|2024Cited by 6
Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of lifeBente Braun, Vivien Häußler, Felix Fischbach et al.|Multiple Sclerosis and Related Disorders|2023Cited by 5
“A second birthday”? Experiences of persons with multiple sclerosis treated with autologous hematopoietic stem cell transplantation—a qualitative interview studyTimo Volz, Christoph Heesen, Anna Sippel et al.|Frontiers in Neurology|2024Cited by 2